The results of clinical trials show that dabrafenib exerts a therapeutic effect in patients with CRC who harbor mutated V600E BRAF with the EGFR inhibitor panitumumab as combination treatment [82]. This evidence concerns the gene BRAF and colorectal carcinoma.